This patent describes compounds that function as vasopressin receptor 2 (V2R) modulators, along with related pharmaceutical compositions, for the treatment of diseases or disorders, including kidney disorders.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: